Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase

Biochemical Pharmacology

Volumn 78, Issue 9, 2009, Pages 1178-1185

  Zhu, Lijun ^a   Zhou, Bingsen ^b   Chen, Xinhuan ^a   Jiang, Hongjuan ^a   Shao, Jimin ^a   Yen, Yun ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

3 Aminopyridine 2 carboxaldehyde thiosemicarbazone (3AP); Heterocyclic carboxaldehyde thiosemicarbazones (HCTs); Mechanism of action; Ribonucleotide reductase; The small subunits M2 and p53R2

Indexed keywords

3 AMINO 4 METHYLPYRIDINE 2 CARBOXALDEHYDE THIOSEMICARBAZONE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 3 METHYL AMINOPYRIDINE 2 CARBOXALDEHYDE THIOSEMICARBAZONE; 3,5 DIAMINOPYRIDINE 2 CARBOXALDEHYDE THIOSEMICARBAZONE; 5 AMINO 4 MORPHOLINOMETHYLPYRIDINE 2 CARBOXALDEHYDE THIOSEMICARBAZONE; 5 AMINOPYRIDINE 2 CARBOXALDEHYDE THIOSEMICARBAZONE; 5 HYDROXY 4 METHYL 1 FORMYLISOQUINOLINE THIOSEMICARBAZONE; 5 METHYL 4 AMINO 1 FORMYLISOQUINOLINE THIOSEMICARBAZONE; FERROUS ION; GEMCITABINE; HETEROCYCLIC COMPOUND; HYDROXYUREA; IRON; REACTIVE OXYGEN METABOLITE; RECOMBINANT ENZYME; RIBONUCLEOTIDE REDUCTASE; THIOSEMICARBAZONE DERIVATIVE; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; CANCER THERAPY; CARCINOMA CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBUNIT; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL;

CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENZYME INHIBITORS; HUMANS; ISOENZYMES; RIBONUCLEOTIDE REDUCTASES; THIOSEMICARBAZONES;

EID: 70249108780     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.06.103     Document Type: Article

References (41)

1. Nordlund P., and Reichard P. Ribonucleotide reductases. Annu Rev Biochem 75 (2006) 681-706
2. Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404 (2000) 42-49
3. Nakano K., Balint E., Ashcroft M., and Vousden K.H. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 19 (2000) 4283-4289
4. Guittet O., Hakansson P., Voevodskaya N., Fridd S., Graslund A., Arakawa H., et al. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 276 (2001) 40647-40651
5. Chabes A.L., Bjorklund S., and Thelander L. S Phase-specific transcription of the mouse ribonucleotide reductase R2 gene requires both a proximal repressive E2F-binding site and an upstream promoter activating region. J Biol Chem 279 (2004) 10796-10807
6. Shao J., Zhou B., Zhu L., Qiu W., Yuan Y.C., Xi B., et al. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res 64 (2004) 1-6
7. Xue L., Zhou B., Liu X., Qiu W., Jin Z., and Yen Y. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res 63 (2003) 980-986
8. Chang L., Zhou B., Hu S., Guo R., Liu X., Jones S.N., et al. ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage. Proc Natl Acad Sci USA 105 (2008) 18519-18524
9. Lozano G., and Elledge S.J. p53 sends nucleotides to repair DNA. Nature 404 (2000) 24-25
10. Kimura T., Takeda S., Sagiya Y., Gotoh M., Nakamura Y., and Arakawa H. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 34 (2003) 440-445
11. Thelander L. Ribonucleotide reductase and mitochondrial DNA synthesis. Nat Genet 39 (2007) 703-704
12. Pontarin G., Ferraro P., Hakansson P., Thelander L., Reichard P., and Bianchi V. p53R2-dependent ribonucleotide reduction provides deoxyribonucleotides in quiescent human fibroblasts in the absence of induced DNA damage. J Biol Chem 282 (2007) 16820-16828
13. Bourdon A., Minai L., Serre V., Jais J.P., Sarzi E., Aubert S., et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet 39 (2007) 776-780
14. Kollberg G., Darin N., Benan K., Moslemi A.R., Lindal S., Tulinius M., et al. A novel homozygous RRM2B missense mutation in association with severe mtDNA depletion. Neuromuscul Disord 19 (2009) 147-150
15. Shao J., Zhou B., Chu B., and Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 6 (2006) 409-431
16. Zhang K., Hu S., Wu J., Chen L., Lu J., Wang X., et al. Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer 8 (2009) 11
17. Giles F.J. A new era for ribonucleoside reductase inhibition. Leuk Res 31 (2007) 1171-1172
18. Okumura H., Natsugoe S., Yokomakura N., Kita Y., Matsumoto M., Uchikado Y., et al. Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 12 (2006) 3740-3745
19. Yanamoto S., Kawasaki G., Yamada S.I., Yoshitomi I., Yoshida H., and Mizuno A. Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/beta-catenin pathway. Oral Oncol (2008) [Epub ahead of print]
20. Liu X., Zhou B., Xue L., Yen F., Chu P., Un F., et al. Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer 6 (2007) 374-381
21. Devlin H.L., Mack P.C., Burich R.A., Gumerlock P.H., Kung H.J., Mudryj M., et al. Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol Cancer Res 6 (2008) 808-818
22. Wang X., Zhenchuk A., Wiman K.G., and Albertioni F. Regulation of p53R2 and its role as potential target for cancer therapy. Cancer Lett 276 (2009) 1-7
23. Kim S.O., Jeong J.Y., Kim M.R., Cho H.J., Ju J.Y., Kwon Y.S., et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 14 (2008) 3083-3088
24. Saban N., and Bujak M. Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. Cancer Chemother Pharmacol April (7) (2009) [Epub ahead of print]
25. Finch R.A., Liu M., Grill S.P., Rose W.C., Loomis R., Vasquez K.M., et al. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 59 (2000) 983-991
26. Xu H., Fairman J.W., Wijerathna S.R., Kreischer N.R., LaMacchia J., Helmbrecht E., et al. The structural basis for peptidomimetic inhibition of eukaryotic ribonucleotide reductase: a conformationally flexible pharmacophore. J Med Chem 51 (2008) 4653-4659
27. Cory J.G., Cory A.H., Rappa G., Lorico A., Liu M.C., Lin T.S., et al. Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo. Adv Enzyme Regul 35 (1995) 55-68
28. Gojo I., Tidwell M.L., Greer J., Takebe N., Seiter K., Pochron M.F., et al. Phase I and pharmacokinetic study of Triapine((R)), a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res 31 (2007) 1173-1181
29. Chaston T.B., Lovejoy D.B., Watts R.N., and Richardson D.R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 9 (2003) 402-414
30. Shao J., Zhou B., Di Bilio A.J., Zhu L., Wang T., Qi C., et al. A ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol Cancer Ther 5 (2006) 586-592
31. Shao J., Zhou B., Zhu L., Bilio A.J., Su L., Yuan Y.C., et al. Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay. Biochem Pharmacol 69 (2005) 627-634
32. Yen Y., Grill S.P., Dutschman G.E., Chang C.N., Zhou B.S., and Cheng Y.C. Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res 54 (1994) 3686-3691
33. Goan Y.G., Zhou B., Hu E., Mi S., and Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycitidine in the human KB cancer cell line. Cancer Res 59 (1999) 4204-4207
34. Heidel J.D., Liu J.Y., Yen Y., Zhou B., Heale B.S., Rossi J.J., et al. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res 13 (2007) 2207-2215
35. Solly K., Wang X., Xu X., Strulovici B., and Zheng W. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol 2 (2004) 363-372
36. Tarpey M.M., Wink D.A., and Grisham M.B. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol 286 (2004) R431-444
37. Liu X., Xue L., and Yen Y. Redox property of ribonucleotide reductase small subunit M2 and p53R2. Methods Mol Biol 477 (2008) 195-206
38. Lassmann G., Thelander L., and Gräslund A. EPR stopped-flow studies of the reaction of the tyrosyl radical of protein R2 from ribonucleotide reductase with hydroxyurea. Biochem Biophys Res Commun 188 (1992) 879-887
39. Nyholm S., Thelander L., and Graslund A. Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea. Biochemistry 32 (1993) 11569-11574
40. Yen Y., Margolin K., Doroshow J., Fishman M., Johnson B., Clairmont C., et al. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol 54 (2004) 331-342
41. Lin Z.P., Belcourt M.F., Cory J.G., and Sartorelli A.C. Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted siRNA sensitizes p53 (-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors. J Biol Chem 279 (2004) 27030-27038